百令胶囊联合氯沙坦钾片对慢性肾脏病患者相关炎性因子的影响

Effects of Bailing capsule combined with losartan potassium tablet on inflammatory factors in patients with chronic kidney disease

目的观察百令胶囊联合氯沙坦钾片治疗慢性肾脏病患者的疗效及对相关炎性因子的影响。方法将2017年3月-2018年10月承德医学院附属医院肾内科收治的80例慢性肾脏病患者随机分成对照组和治疗组,各40例。对照组给予氯沙坦钾片50 mg/d口服,治疗组同时给予氯沙坦钾片与百令胶囊2.0 g/d、3次/d口服。2组治疗时间均为6个月。检测2组治疗前后不同时点肾功能指标[血肌酐(SCr)、尿素氮(BUN)、24 h尿蛋白定量]及炎性因子[白细胞诱素1(Lkn-1)、血管内皮生长因子(VEGF)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、转化生长因子β1(TGF-β1)]水平,评估治疗效果。结果对照组治疗1个月、3个月后SCr、BUN、24 h尿蛋白定量及Lkn-1、VEGF、Hs-CRP、TNF-α、TGF-β1与治疗前比较差异均无统计学意义(P均>0.05),治疗6个月后均明显低于治疗前(P均<0.05);治疗组治疗1个月后上述指标与治疗前比较差异均无统计学意义(P均>0.05),治疗3个月、6个月后均明显低于治疗前(P均<0.05);治疗组治疗6个月后上述指标均明显低于对照组(P均<0.05)。治疗组总体疗效明显优于对照组(P<0.05)。结论百令胶囊联合氯沙坦钾片治疗慢性肾脏病可以减少尿蛋白,改善肾功能,有效延缓肾纤维化,机制与炎性反应有关。

Objective It is to observe the curative effect of Bailing capsule combined with losartan potassium tablet on chronic kidney disease and its effect on related inflammatory factors. Methods 80 patients with chronic kidney disease treated at the Affiliated Hospital of Chengde Medical College from March 2017 to October 2018 were randomly divided into a control group and a treatment group, with 40 patients in each group. The control group was given losartan potassium tablets 50 mg/d orally, the treatment group was given losartan potassium tablets 50 mg/d orally with Bailing capsule 2.0 g/d 3 times a day. Both groups were treated for 6 months. The renal function indicators [serum creatinine(SCr), urea nitrogen(BUN), 24 h protein quantification], inflammatory factors [leukin-1(Lkn-1), vascular endothelial growth factor(VEGF), and hypersensitive C-reactive protein(hs-CRP), tumor necrosis factor α(TNF-α), transforming growth factor β1(TGF-β1)]were measured before and after treatment in the two groups, and the curative effect was assessed. Results There was no significant difference in SCr, BUN, 24 h urinary protein and Lkn-1, VEGF, hs-CRP, TNF-α, TGF-β1 in the control group after treatment for 1 month and 3 months(P>0.05), after 6 months of treatment, they were significantly lower than those before treatment(P<0.05). There was no statistically significant difference in the above indicators after 1 month of treatment in the treatment group(P>0.05);after 3,6 months of treatment, they were significantly lower than those before treatment(P<0.05);the above indexes were significantly lower in the treatment group than those in the control group after 6 months of treatment(P<0.05). The overall effect of the treatment group was significantly better than that of the control group(P<0.05). Conclusion Bailing capsule combined with losartan potassium tablets can reduce urinary protein, improve renal function, and effectively delay renal fibrosis in the treatment of chronic kidney disease. The mechanism may be related to the inhibition of inflammatory response.